2nd Quarter - Report — DELAHUNT GROUP, LLC for HEALIANCE PHARMACEUTICALS (2014)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

DELAHUNT GROUP, LLC

Client

HEALIANCE PHARMACEUTICALS

Income

$50,000

Expenses

—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
2nd Quarter - Report (this page)	Jul 11, 2014	$50,000	Replaced
2nd Quarter - Amendment	Jan 9, 2015	$50,000	Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to issuance of supplemental OFAC license.

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from work for client.

Lobbyist	Covered position, as disclosed
WILLIAM DELAHUNT	—
JOHN H. SUNUNU	—

Contacted: Natl Security Agency (NSA); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); SENATE

Health Issues HCR

Issues related to issuance of supplemental OFAC license.

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from work for client.

Lobbyist	Covered position, as disclosed
WILLIAM DELAHUNT	—
JOHN H. SUNUNU	—

Contacted: State, Dept of (DOS); Natl Security Agency (NSA); SENATE; HOUSE OF REPRESENTATIVES

Foreign Relations FOR

Issues related to issuance of supplemental OFAC license.

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from work for client.

Lobbyist	Covered position, as disclosed
WILLIAM DELAHUNT	—
JOHN H. SUNUNU	—

Contacted: HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Natl Security Agency (NSA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.